Bountogo M et al., 2010-03-29: Open-label phase II study of methylene blue alone in 60 semi-immune Burkinabe adults at 390 mg twice daily for 7, 5 or 3 days. PCR-corrected adequate clinical and parasitological response at day 28 was 72% (7 days), 58% (5 days) and 85% (3 days); the authors conclude methylene blue acts slowly, needs at least seven days alone, and should be combined with a fast-acting antimalarial.
MB monotherapy (390 mg twice daily) was given sequentially to groups of 20 adults for 7 days (MB7), 5 days (MB5) and 3 days (MB3), respectively.
Abstract
Bountogo M et al., 2010-03-29: Open-label phase II study of methylene blue alone in 60 semi-immune Burkinabe adults at 390 mg twice daily for 7, 5 or 3 days. PCR-corrected adequate clinical and parasitological response at day 28 was 72% (7 days), 58% (5 days) and 85% (3 days); the authors conclude methylene blue acts slowly, needs at least seven days alone, and should be combined with a fast-acting antimalarial. Study type: open-label controlled sequential-dose phase II study; N=60 semi-immune adults, Nouna, Burkina Faso. MB 390 mg twice daily orally (about 13 mg/kg/day at 60 kg), 3/5/7-day arms. Comparator: the other dose-duration arms (no placebo). Primary outcome: PCR-corrected ACPR day 28 (72%/58%/85%). Common adverse event: self-limiting dysuria. Funder/COI not stated in retrieved abstract record. Registry: ClinicalTrials.gov NCT00917202 (completed, no results posted). Study type: controlled study.
